Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 9 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 4 |
| Urological Disorders Therapeutics to 2017 - Introduction | 13 | 2 |
| GBI Research Report Guidance | 14 | 1 |
| Urological Disorders Therapeutics to 2017 - Market Overview | 15 | 13 |
| Introduction | 15 | 1 |
| Revenue Forecasts for the Global Urological Disorders Market | 16 | 1 |
| Revenue | 16 | 1 |
| Generic Share | 17 | 1 |
| Annual Cost of Therapy | 18 | 2 |
| Treatment Usage Patterns | 20 | 2 |
| Diseased Population | 22 | 1 |
| Treatment Seeking Population | 23 | 1 |
| Diagnosis Population | 24 | 1 |
| Prescription Population | 25 | 1 |
| Urological Disorders Market Drivers and Restraints | 26 | 1 |
| Urological Disorders Market Drivers | 26 | 1 |
| Steady Increase in the BPH and UTI Prevalence Population | 26 | 1 |
| Rapid Uptake of Branded Products due to Better Efficacy in BPH | 26 | 1 |
| Patent Expiries of Branded Drugs will Make them More Affordable to Patients | 26 | 1 |
| Urological Disorders Market Restraints | 27 | 1 |
| Unwillingness to Seek Medical Help for UI and IC | 27 | 1 |
| Patent Expiries of Major Blockbusters including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenue | 27 | 1 |
| Non Pharmacological Therapy Recommended for UI and BPH | 27 | 1 |
| Urological Disorders Therapeutics to 2017 - Geographical Landscape | 28 | 28 |
| Revenue by Geography | 28 | 2 |
| The US | 30 | 1 |
| Revenue | 30 | 2 |
| Annual Cost of Therapy | 32 | 1 |
| Treatment Usage Patterns | 33 | 2 |
| Diseased Population | 35 | 1 |
| Treatment Seeking Population | 36 | 1 |
| Diagnosed Population | 37 | 1 |
| Prescription Population | 38 | 1 |
| Top Five Countries in Europe | 39 | 1 |
| Revenue | 39 | 2 |
| Annual Cost of Therapy | 41 | 1 |
| Treatment Usage Patterns | 42 | 2 |
| Diseased Population | 44 | 1 |
| Treatment Seeking Population | 45 | 1 |
| Diagnosed Population | 46 | 1 |
| Prescription Population | 47 | 1 |
| Japan | 48 | 1 |
| Revenue | 48 | 1 |
| Annual Cost of Therapy | 49 | 1 |
| Treatment Usage Patterns | 50 | 2 |
| Diseased Population | 52 | 1 |
| Treatment Seeking Population | 53 | 1 |
| Diagnosed Population | 54 | 1 |
| Prescription Population | 55 | 1 |
| Urological Disorders Therapeutics to 2017 - Therapeutic Landscape | 56 | 47 |
| Benign Prostatic Hyperplasia Market | 56 | 1 |
| Introduction | 56 | 1 |
| Treatment Algorithm | 56 | 1 |
| Revenue | 57 | 1 |
| Generics Share | 58 | 2 |
| Annual Cost of Therapy | 60 | 2 |
| Treatment Usage Patterns | 62 | 2 |
| Diseased Population | 64 | 1 |
| Treatment Seeking Population | 65 | 1 |
| Diagnosed Population | 66 | 1 |
| Prescription Population | 67 | 1 |
| Urinary Incontinence Market | 68 | 1 |
| Introduction | 68 | 1 |
| Treatment Algorithm | 69 | 2 |
| Revenue | 71 | 1 |
| Generics Share | 72 | 2 |
| Annual Cost of Therapy | 74 | 1 |
| Treatment Usage Patterns | 75 | 2 |
| Diseased Population | 77 | 1 |
| Treatment Seeking Population | 78 | 1 |
| Diagnosed Population | 79 | 1 |
| Prescription Population | 80 | 1 |
| Urinary Tract Infections Market | 81 | 1 |
| Introduction | 81 | 1 |
| Treatment Algorithm | 81 | 1 |
| Revenue | 82 | 1 |
| Generics Share | 83 | 2 |
| Annual Cost of Therapy | 85 | 1 |
| Treatment Usage Patterns | 86 | 2 |
| Diseased Population | 88 | 1 |
| Treatment Seeking Population | 89 | 1 |
| Diagnosed Population | 90 | 1 |
| Prescription Population | 91 | 1 |
| Interstitial Cystitis Market | 92 | 1 |
| Introduction | 92 | 1 |
| Treatment Algorithm | 92 | 1 |
| Revenue | 93 | 1 |
| Generics Share | 94 | 2 |
| Annual Cost of Therapy | 96 | 1 |
| Treatment Usage Patterns | 97 | 1 |
| Diseased Population | 98 | 2 |
| Treatment Seeking Population | 100 | 1 |
| Diagnosed Population | 101 | 1 |
| Prescription Population | 102 | 1 |
| Urological Disorders Therapeutics to 2017 - Pipeline Product Analysis | 103 | 16 |
| Introduction | 103 | 5 |
| Product Pipeline by Indication | 108 | 1 |
| Benign Prostatic Hyperplasia | 108 | 1 |
| Introduction | 108 | 1 |
| Urinary Incontinence | 109 | 1 |
| Introduction | 109 | 1 |
| Urinary Tract Infections | 110 | 1 |
| Introduction | 110 | 1 |
| Interstitial Cystitis | 111 | 1 |
| Introduction | 111 | 1 |
| Profiles of Key Late-Stage Drugs in the Urological Disorders Market | 112 | 1 |
| Benign Prostatic Hyperplasia | 112 | 1 |
| NX-1207 | 112 | 1 |
| PRX302 | 113 | 1 |
| Urinary Incontinence | 114 | 1 |
| YM178 | 114 | 1 |
| GRC 6211 | 115 | 1 |
| Urinary Tract Infections | 115 | 1 |
| Finafloxacin | 115 | 1 |
| CXA-101 | 116 | 1 |
| Interstitial Cystitis | 116 | 1 |
| URG101 | 116 | 1 |
| PSD597 | 117 | 2 |
| Urological Disorders Therapeutics to 2017 - Competitive Landscape | 119 | 16 |
| Drugs for Major Urological Disorders | 119 | 1 |
| Duodart | 119 | 1 |
| Overview | 119 | 1 |
| Efficacy | 119 | 1 |
| Safety | 119 | 1 |
| Clinical Study Details | 119 | 1 |
| Dutasteride (Avodart) | 120 | 1 |
| Overview | 120 | 1 |
| Efficacy | 120 | 1 |
| Safety | 120 | 1 |
| Clinical Study Details | 120 | 1 |
| Ditropan (Oxybutynin chloride) | 121 | 1 |
| Overview | 121 | 1 |
| Efficacy | 121 | 1 |
| Safety | 121 | 1 |
| Clinical Study Details | 121 | 1 |
| Tamsulosin (Flomax, Harnal) | 121 | 1 |
| Overview | 121 | 1 |
| Efficacy | 121 | 1 |
| Safety | 122 | 1 |
| Clinical Study Details | 122 | 1 |
| Enablex (Darifenacin) | 122 | 1 |
| Overview | 122 | 1 |
| Efficacy | 122 | 1 |
| Safety | 122 | 1 |
| Clinical Study Details | 123 | 1 |
| Sanctura XR (Trospium Chloride) | 123 | 1 |
| Overview | 123 | 1 |
| Efficacy | 123 | 1 |
| Safety | 123 | 1 |
| Clinical Study Details | 123 | 1 |
| Doribax (Doripenem) | 124 | 1 |
| Overview | 124 | 1 |
| Efficacy | 124 | 1 |
| Safety | 124 | 1 |
| Clinical Study Details | 124 | 1 |
| Detrol/Detrol LA (Tolterodine tartrate) | 125 | 1 |
| Overview | 125 | 1 |
| Efficacy | 125 | 1 |
| Safety | 125 | 1 |
| Clinical Study Details | 125 | 1 |
| Vesicare (Solifenacin Succinate) | 125 | 1 |
| Overview | 125 | 1 |
| Efficacy | 125 | 1 |
| Safety | 126 | 1 |
| Clinical Study Details | 126 | 1 |
| Alfuzosin (Xatral, Uroxatral) | 126 | 1 |
| Overview | 126 | 1 |
| Efficacy | 126 | 1 |
| Safety | 126 | 1 |
| Clinical Study Details | 127 | 1 |
| Levaquin (levofloxacin) | 127 | 1 |
| Overview | 127 | 1 |
| Efficacy | 127 | 1 |
| Safety | 128 | 1 |
| Clinical Study Details | 128 | 1 |
| Toviaz (Fesoterodine Fumarate) | 128 | 1 |
| Overview | 128 | 1 |
| Efficacy | 128 | 1 |
| Safety | 128 | 1 |
| Clinical Study Details | 129 | 1 |
| Market Share Analysis | 129 | 1 |
| Competitive Profiling | 130 | 1 |
| Johnson &Johnson | 130 | 1 |
| Business Overview | 130 | 1 |
| SWOT | 130 | 1 |
| Boehringer Ingelheim | 131 | 1 |
| Business Overview | 131 | 1 |
| SWOT | 131 | 1 |
| Astellas Pharma | 132 | 1 |
| Business Overview | 132 | 1 |
| SWOT | 132 | 1 |
| GlaxoSmithKline | 133 | 1 |
| Business Overview | 133 | 1 |
| SWOT | 133 | 1 |
| Pfizer | 134 | 1 |
| Business Overview | 134 | 1 |
| SWOT | 134 | 1 |
| Urological Disorders Therapeutics to 2017 - M&A Landscape | 135 | 16 |
| Overview | 135 | 1 |
| M&A Deals (2004-2011) | 136 | 1 |
| By Indication | 136 | 1 |
| By Year | 137 | 1 |
| By Deal Type | 138 | 1 |
| By Deal Sub-Type | 139 | 1 |
| Geography | 140 | 1 |
| Value | 141 | 2 |
| Licensing Deals | 143 | 1 |
| By Indication | 143 | 1 |
| By Year | 144 | 1 |
| By Geography | 145 | 1 |
| By Value | 146 | 1 |
| Co-Development Deals | 147 | 1 |
| By Indication | 147 | 1 |
| By Year | 148 | 1 |
| By Geography | 149 | 1 |
| By Value | 150 | 1 |
| Urological Disorders Therapeutics to 2017 - Appendix | 151 | 8 |
| Market Definitions | 151 | 1 |
| Abbreviations | 151 | 1 |
| Research Methodology | 152 | 6 |
| Coverage | 152 | 1 |
| Secondary Research | 153 | 1 |
| Primary Research | 153 | 1 |
| Therapeutic Landscape | 154 | 1 |
| Epidemiology-based Forecasting | 154 | 2 |
| Market Size by Geography | 156 | 1 |
| Geographical Landscape | 157 | 1 |
| Pipeline Analysis | 157 | 1 |
| Competitive Landscape | 157 | 1 |
| Expert Panel Validation | 157 | 1 |
| Contact Us | 157 | 1 |
| Disclaimer | 157 | 1 |
| Sources | 158 | 1 |